ABSTRACT
Background Prisons and jails are high-risk settings for COVID-19 transmission, morbidity, and mortality. COVID-19 vaccines may substantially reduce these risks, but evidence is needed of their effectiveness for incarcerated people, who are confined in large, risky congregate settings.
Methods We conducted a retrospective cohort study to estimate effectiveness of mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), against confirmed SARS-CoV-2 infections among incarcerated people in California prisons from December 22, 2020 through March 1, 2021. The California Department of Corrections and Rehabilitation provided daily data for all prison residents including demographic, clinical, and carceral characteristics, as well as COVID-19 testing, vaccination status, and outcomes. We estimated vaccine effectiveness using multivariable Cox models with time-varying covariates that adjusted for resident characteristics and infection rates across prisons.
Findings Among 60,707 residents in the cohort, 49% received at least one BNT162b2 or mRNA-1273 dose during the study period. Estimated vaccine effectiveness was 74% (95% confidence interval [CI], 64−82%) from day 14 after first dose until receipt of second dose and 97% (95% CI, 88−99%) from day 14 after second dose. Effectiveness was similar among the subset of residents who were medically vulnerable (74% [95% CI, 62−82%] and 92% [95% CI, 74−98%] from 14 days after first and second doses, respectively), as well as among the subset of residents who received the mRNA-1273 vaccine (71% [95% CI, 58−80%] and 96% [95% CI, 67−99%]).
Conclusions Consistent with results from randomized trials and observational studies in other populations, mRNA vaccines were highly effective in preventing SARS-CoV-2 infections among incarcerated people. Prioritizing incarcerated people for vaccination, redoubling efforts to boost vaccination and continuing other ongoing mitigation practices are essential in preventing COVID-19 in this disproportionately affected population.
Funding Horowitz Family Foundation, National Institute on Drug Abuse, Centers for Disease Control and Prevention, National Science Foundation, Open Society Foundation, Advanced Micro Devices.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported in part by the COVID-19 Emergency Response Fund at Stanford, established with a gift from the Horowitz Family Foundation; a grant (R37-DA15612), awarded to Dr. Goldhaber-Fiebert and Dr. Salomon, from the National Institute on Drug Abuse; a grant (NU38OT000297-02), awarded to Dr. Salomon, from the Centers for Disease Control and Prevention through the Council of State and Territorial Epidemiologists; a grant (DGE-1656518), awarded to Ms. Chin, from the National Science Foundation Graduate Research Fellowship Program; and a grant (OR2020-69521), awarded to Dr. Alarid-Escudero, from Open Society Foundations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review board (IRB) at Stanford University (protocol #55835). The IRB approval of the study included a waiver of consent, on the basis that CDCR provided the Stanford research team with a limited data set without direct identifiers, the data had been collected for operational purposes, and the study could not practicably be carried out otherwise. It was reviewed by CDC and conducted according to applicable federal law and CDC policy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Data Availability
Data not available due to Data Use Agreement between Stanford University and the California Department of Corrections and Rehabilitation.
